Healthcare / Medical DevicesShenzhen
$16.09
+0.21 (+1.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-160.9M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-0.3%
↓Gross Margin
36.2%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-70.7%
FCF CAGR
—
FCF margin
-60.7%
FCF / Net income
9.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $265.1M · net income $-16.5M · FCF $-160.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $265.1M | $265.1M | $350.1M | $749.5M | $10.53B |
| Net Income | $-16.5M | $-16.5M | $74.5M | $74.9M | $4.21B |
| EBITDA | $-9.0M | $-9.0M | $96.7M | $233.8M | $5.14B |
| EPS | -0.07 | -0.07 | 0.33 | 0.33 | 18.31 |
| Gross Margin | 36.2% | 36.2% | 53.9% | 54.3% | 66.8% |
| Operating Margin | -40.0% | -40.0% | -4.2% | 13.4% | 57.2% |
| Net Margin | -6.2% | -6.2% | 21.3% | 10.0% | 40.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
| Current Ratio | 18.35 | 18.35 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-160.9M | $-160.9M | $-269.8M | $282.5M | $3.70B |
| Returns | |||||
| ROE | -0.3% | -0.3% | 1.3% | 1.2% | 64.7% |
| Valuation | |||||
| P/E | — | — | 56.67 | 69.39 | 2.14 |
| EV/EBITDA | — | — | 38.70 | 18.11 | 1.29 |
| P/B | 0.68 | 0.68 | 0.72 | 0.86 | 1.38 |
| Growth & Yield | |||||
| Revenue Growth | -24.3% | -24.3% | -53.3% | -92.9% | — |
| EPS Growth | -121.2% | -121.2% | 0.0% | -98.2% | — |
| Dividend Yield | 7.6% | 7.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.2%
Start / end P/E
n/dx → n/dx
EPS bridge
0.33 → -0.07
Residual
-16.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.